Verastem

VSTM NASDAQ
1.490
-0.050
-3.25%
After Hours: 1.490 0 0.00% 16:54 05/22 EDT
Open
1.520
Prev Close
1.540
High
1.540
Low
1.430
Volume
1.17M
Avg Vol (3M)
2.92M
52 Week High
10.35
52 Week Low
1.200
% Turnover
1.59%
Market Cap
110.08M
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Company Profile

Verastem, Inc., is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. It is also developing a dual inhibitor of PI3K-delta and PI3K-gamma, which has completed Phase 2 study in indolent non-hodgkin lymphoma. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma.
MORE >

Recently

Name
Price
%Change